CN112625053A - 7-ACA with low content of maximum unknown simple impurity and preparation method thereof - Google Patents
7-ACA with low content of maximum unknown simple impurity and preparation method thereof Download PDFInfo
- Publication number
- CN112625053A CN112625053A CN202011628328.XA CN202011628328A CN112625053A CN 112625053 A CN112625053 A CN 112625053A CN 202011628328 A CN202011628328 A CN 202011628328A CN 112625053 A CN112625053 A CN 112625053A
- Authority
- CN
- China
- Prior art keywords
- aca
- cephalosporin
- preparation
- solution
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/18—7-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
- C12P35/02—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin by desacylation of the substituent in the 7 position
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/10—Process efficiency
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cephalosporin Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses 7-ACA with low content of maximum unknown single impurity and a preparation method thereof. The purity of the 7-ACA is above 99.10%, and the maximum content of unknown single impurity is below 0.152%; the preparation method comprises the following steps: (1) adding an antioxidant into the cephalosporin C preparation solution, and uniformly mixing to obtain a pretreatment solution; (2) carrying out enzymolysis reaction on the pretreatment solution obtained in the step (1) and enzyme to obtain 7-ACA enzymolysis solution; (3) and (3) performing ultrafiltration, crystallization and filtration on the enzymolysis liquid obtained in the step (2), and drying the solid to obtain the 7-ACA. According to the invention, the antioxidant is added into the cephalosporin C preparation solution, so that the generation of the maximum unknown single impurity in the enzymolysis reaction process can be effectively reduced, and the maximum unknown single impurity content in the final product 7-ACA can be effectively reduced; the method is simple to operate, is suitable for industrial mass production, overcomes the technical problem that the prior art is difficult to prepare the high-purity 7-ACA with low unknown single impurity content in the industrial mass production, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to 7-ACA with low content of maximum unknown single impurity and a preparation method thereof.
Background
7-ACA (7-aminocephalosporanic acid) is white or white-like crystalline powder which is an important parent nucleus for synthesizing cephalosporin antibiotics; it contains two reactive groups: the acetoxyl group at the 3-position and the amino group at the 7-position can form various cephalosporin antibiotics with different properties by connecting different side chains on the two active groups, including cefazolin sodium, cefotaxime sodium, cefotriazine sodium, cefoperazone sodium, ceftazidime sodium, cefuroxime sodium and the like. Cephalosporin antibiotics are widely used because of their advantages of broad antimicrobial spectrum, strong antimicrobial action, less allergic reaction, partial cross-allergenicity with penicillin, different degrees of stability to beta-lactamase, etc.
The purity of 7-ACA directly influences the quality of downstream synthesized products, so that the synthesis of high-purity 7-ACA is very important for the production of high-quality cephalosporin antibiotics. The currently reported method for synthesizing 7-ACA is to directly convert cephalosporin C into 7-ACA by adopting immobilized cephalosporin C acylase under certain reaction conditions. However, the method has low purity of 7-ACA obtained by enzymolysis due to the influence of the production conditions of enzymolysis reaction, and directly influences the quality of 7-ACA products.
Chinese patent application CN103555807A discloses a method for preparing 7-ACA, which comprises the following steps: (1) pretreatment of cephalosporin C (CPC) liquid: 10 l of cephalosporin C (CPC) fermentation filtrate (750mM, equivalent to 311 g of pure CPC) were taken, filtered through a1 μm membrane and adjusted to pH 10 with ammonia. (2) Controlling reaction conditions: adding 1800 g of (NRB-103) enzyme into a reactor, washing twice, adding CPC solution, quickly stirring, controlling the pH to be 8-10 by using ammonia water, reacting for 30 minutes, and ensuring that the 7-ACA conversion rate is 98%. (3) Treatment of lysate (7-ACA solution): to 15 liters of the obtained 7-ACA solution was added 100 g of Na2S2O4Adjusting pH to 7 with ammonia water, adding Tween 80 and 10 ml, adding dichloromethane 2000 ml, stirring for 10 min, separating phases, adding activated carbon 20 g into the water phase, adding EDTA10 g, stirring for 15 min, and filtering to remove carbon to obtain 7-ACA treatment solution. (4)7-ACA crystallization: 3 mol of hydrochloric acid is dripped into the 7-ACA treatment solution to ensure that the pH is 5, after the crystallization is completed, the crystals are filtered out, the filtered mother liquor is collected, then 300 ml of acetone is used for washing the crystals, and the crystals are dried in vacuum until the weight yield is 63.7 percent and the purity is 99.5 percent.
However, this method is complicated in operation and requires the use of Na2S2O4Tween 80 and EDTA 10; moreover, the application does not make further analyses of the impurities in the product 7-ACA and does not refer to 7-AAnalysis of the content of impurities in CA is not described in any way to remove unknown impurities from 7-ACA. More importantly, the method described in the application is a method suitable for small-scale synthesis in a laboratory, and cannot comprehensively reflect the actual situation of industrial large-scale production; at present, no report on the preparation of 7-ACA with high purity and low content of unknown impurities suitable for industrial mass production is found.
Therefore, the development of a method which is simple to operate, suitable for industrial mass production and capable of reducing the content of unknown single impurities in 7-ACA has important significance.
Disclosure of Invention
The invention aims to provide a preparation method which is simple to operate and suitable for industrial mass production and can reduce the maximum unknown simple impurity content in 7-ACA, and the invention also aims to provide the 7-ACA with low maximum unknown simple impurity content prepared by the method, and solve the problem that the prior process (especially the industrial mass production process) can not effectively reduce the unknown simple impurity content in the 7-ACA.
The invention provides 7-aminocephalosporanic acid with low content of maximum unknown single impurity, wherein the purity of the 7-aminocephalosporanic acid is more than 99.10 percent, and the content of the maximum unknown single impurity is less than 0.152 percent; the retention time of the largest unknown single impurity relative to 7-aminocephalosporanic acid under the following HPLC chromatographic conditions was 1.60 ± 0.10:
HPLC chromatographic conditions:
a chromatographic column: c18A chromatographic column is arranged on the top of the chromatographic column,
mobile phase: phase A: and the volume ratio of the phase B is 97:3, wherein the phase A is 0.02mol/L ammonium acetate solution, and the phase B is acetonitrile.
Further, in the HPLC chromatographic conditions, the pH of the phase A is 6.2 +/-0.02; flow rate: 1.0 ml/min; column temperature: 35 ℃; detection wavelength: 254 nm.
The invention also provides a preparation method of 7-aminocephalosporanic acid with low content of maximum unknown single impurity, which comprises the following steps:
(1) adding an antioxidant into the cephalosporin C preparation solution, and uniformly mixing to obtain a pretreatment solution;
(2) carrying out enzymolysis reaction on the pretreatment solution obtained in the step (1) and enzyme to obtain 7-aminocephalosporanic acid enzymatic hydrolysate;
(3) and (3) performing ultrafiltration, crystallization and filtration on the enzymolysis liquid obtained in the step (2), and drying the solid to obtain the 7-aminocephalosporanic acid.
Further, in the step (1), the antioxidant is one or a mixture of more than two of sodium bisulfite, sodium sulfite, sulfurous acid and sodium hydrosulfite;
and/or the antioxidant accounts for 0.20-0.30 wt.% of the mass of the cephalosporin C preparation liquid.
Further, in the step (1), the antioxidant is sodium bisulfite;
and/or the mass of the antioxidant is 0.25 wt.% per mill of the mass of the cephalosporin C preparation liquid.
Further, in the step (1), the cephalosporin C preparation solution is a cephalosporin C aqueous solution;
the titer of the cephalosporin C preparation liquid is 20000-30000 mu g/mL;
and/or the pH value of the pre-cephalosporin C preparation liquid is 7.5 +/-0.5.
Further, in the step (1), the titer of the cephalosporin C preparation solution is 22500 mug/mL;
and/or the pH value of the pre-cephalosporin C preparation liquid is 7.5.
Further, in the step (2), the enzyme is immobilized cephalosporin C acylase; the pH value of the enzymolysis reaction is 8.0-9.0, the temperature is 10-20 ℃, and the time is 50-120 minutes;
and/or in the step (3), the cut-off molecular weight of an ultrafiltration membrane adopted in ultrafiltration is 4000-6000 daltons; the crystal is isoelectric point crystal, and the pH value during the crystallization is 5.0-6.0.
Further, in the step (2), the pH value of the enzymolysis reaction is 8.3, the temperature is 14 ℃, and the time is 80 minutes.
Further, in the step (3), the ultrafiltration membrane adopted by ultrafiltration has a molecular weight cutoff of 5000 daltons; the pH at the time of the crystallization was 5.3.
Compared with the prior art, the 7-ACA prepared by the invention has the beneficial effects that: the prepared 7-ACA has high purity (more than 99.10 percent), and the maximum content of unknown single impurities is less than 0.152 percent, thereby providing a high-quality raw material for preparing high-quality cephalosporin antibiotics.
Compared with the prior art, the method for preparing the 7-ACA has the beneficial effects that:
(1) according to the invention, the antioxidant is added into the cephalosporin C preparation solution, so that the generation of the largest unknown single impurity in the enzymolysis reaction process can be effectively reduced, and the 7-ACA enzymolysis solution with low impurity content is obtained;
(2) according to the invention, the 7-ACA enzymolysis liquid with low impurity content is subjected to ultrafiltration and crystallization to further separate impurities, so that the maximum unknown single impurity content in the obtained 7-ACA finished product is obviously reduced, the problem that the prior art cannot effectively further reduce the unknown single impurity content in the 7-ACA is solved, and the 7-ACA with low unknown single impurity content and high purity is obtained;
(3) the invention is matched with specific enzymolysis reaction conditions and crystallization conditions, and the maximum unknown single impurity content in the obtained 7-ACA finished product is reduced, and simultaneously, higher production yield is ensured;
(4) the invention adopts the ultrafiltration membrane with the molecular weight cutoff of 5000 daltons, which has effective interception effect on micromolecular impurities and microorganisms in the feed liquid;
(5) the method of the invention is simple to operate, is suitable for industrial mass production, and overcomes the problem that the prior art is difficult to prepare the 7-ACA with low unknown single impurity content and high purity in the industrial mass production.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 is an HPLC chromatogram of the finished product of 7-ACA obtained in example 8; wherein D-7-ACA is known impurity 3-deacetyl-7-aminocephalosporanic acid, and DO-7-ACA is deacetoxy-7-aminocephalosporanic acid.
FIG. 2 is an HPLC chromatogram of the finished 7-ACA product obtained in comparative example 1; wherein D-7-ACA is known impurity 3-deacetyl-7-aminocephalosporanic acid, and DO-7-ACA is deacetoxy-7-aminocephalosporanic acid.
Detailed Description
The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.
The cephalosporin C preparation liquid is self-made and is a high-purity cephalosporin C water solution extracted from cephalosporin C fermentation liquid, and the specific titer and pH of the cephalosporin C preparation liquid refer to examples 1-8.
The immobilized cephalosporin C acylase is purchased from Aimejian Chinese biological medicine, Inc., and the enzyme activity is 80-130U/g. The immobilized cephalosporin C acylase can also be prepared by self.
The ultrafiltration membrane is purchased from Sanda membrane technology (Xiamen) Co., Ltd, the membrane core is roll type made of polyether sulfone material, and the molecular weight cutoff is 5000 Dalton.
The preparation methods of the following examples 1 to 8 and comparative example 1 are mass production, and the dosage of the raw material cephalosporin C preparation solution is 4000 to 6000L.
EXAMPLE 1 Process for the preparation of 7-ACA with a Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 21500 mu g/mL and the pH of 7.0, adding 0.2 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 2 Process for the preparation of 7-ACA with a Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 22000 mu g/mL and the pH of 7.5, adding 0.3 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 3 Process for the preparation of 7-ACA with a Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 22500 mu g/mL and the pH of 7.3, adding 0.23 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 4 Process for preparing 7-ACA with Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 25000 mu g/mL and the pH of 7.7, adding 0.27 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 5 Process for preparing 7-ACA with Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 23500 mu g/mL and the pH value of 8.0, adding 0.3 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 6 Process for preparing 7-ACA with Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 21000 mu g/mL and the pH value of 7.2, adding 0.2 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 7 Process for preparing 7-ACA with Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 20000 mu g/mL and the pH of 7.5, adding 0.23 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
EXAMPLE 8 Process for preparing 7-ACA with Low content of maximum unknown Monohybrid according to the invention
The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 22500 mu g/mL and the pH of 7.5, adding 0.25 wt.% of sodium bisulfite, and uniformly mixing to obtain a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
Comparative example 1 comparative Process for preparing 7-ACA
Comparative example 1 differs from example 8 only in that no sodium bisulfite was added in step (1). The method specifically comprises the following steps:
(1) taking a cephalosporin C preparation solution with the titer of 22500 mu g/mL and the pH of 7.5 as a pretreatment solution;
(2) reacting the pretreatment solution obtained in the step (1) with immobilized cephalosporin C acylase, controlling the reaction temperature to be 14 ℃, the reaction pH to be 8.3, and the reaction time to be 80 minutes to obtain 7-ACA acylase after the reaction is finished;
(3) and (3) ultrafiltering the acylation liquid collected in the step (2) by using an ultrafiltration membrane, adjusting the pH value to 5.3 by using 10% hydrochloric acid, performing isoelectric point crystallization to obtain 7-ACA crystals, and filtering and drying to obtain the 7-ACA finished product.
The beneficial effects of the present invention are demonstrated by the following experimental examples.
Experimental example 1 quality test of 7-ACA finished product obtained by the method of the present invention
(1) Experimental methods
a. The purity of 7-ACA and the maximum unknown single impurity content in the 7-ACA finished products obtained in examples 1-8 and comparative example 1 were respectively detected by a High Performance Liquid Chromatography (HPLC) method, and the 7-ACA finished products were subjected to parallel detection for 3 times and averaged. Wherein the maximum unknown single impurity content refers to the impurity with the highest content except the known impurities, namely the substance with the retention time of 1.60 +/-0.10 relative to 7-aminocephalosporanic acid under the following chromatographic conditions.
HPLC chromatographic conditions:
a chromatographic column: c18；4.6mm*250mm.5μm；
Mobile phase: phase A: the volume ratio of the phase B is 97:3, wherein the phase A is 0.02mol/L ammonium acetate solution (pH is adjusted to 6.2 +/-0.02 by glacial acetic acid), and the phase B is acetonitrile;
flow rate: 1.0 ml/min;
column temperature: 35 ℃;
detection wavelength: 254 nm;
sample introduction amount: 10 mu l of the mixture;
collecting time: 18min (at least 2 times the retention time of the main peak).
b. The enzymatic hydrolysis yields of the methods described in examples 1 to 8 and comparative example 1 were calculated, respectively, according to the following formula:
the enzymolysis yield is 7-ACA acylation liquid 7-ACA total billion/pretreatment liquid cephalosporin C total billion.
c. The yields of the 7-ACA finished products of the methods described in examples 1 to 8 and comparative example 1 were calculated according to the following formulas:
the yield of the 7-ACA finished product is equal to the weight of the 7-ACA finished product/the weight of the cephalosporin C in the cephalosporin C preparation liquid.
(2) Results of the experiment
TABLE 1 purity, maximum unknown Monohybrid content, enzymatic hydrolysis yield and yield of 7-ACA finished product in examples 1-8 and comparative example 1
The results are shown in table 1 and fig. 1 to 2, and it can be seen that:
the purity of the 7-ACA finished product prepared by the method in the embodiments 1-8 of the invention is above 99.10%, the maximum unknown single impurity content is below 0.152%, the enzymolysis yield is above 62.42%, and the yield of the 7-ACA finished product is above 57.50%; in particular, the purity of the 7-ACA finished product prepared by the method in the embodiment 8 is as high as 99.14%, the maximum content of unknown single impurities is as low as 0.143%, the enzymolysis yield is as high as 62.67%, the yield of the 7-ACA finished product is as high as 57.60%, and the effect is optimal.
Compared with the comparative example 1, under the same other conditions, the maximum unknown single impurity content of the obtained 7-ACA finished product is obviously reduced (the reduction rate reaches 39.41 percent on the basis of the comparative example 1) only by adding 0.25 per thousand of sodium bisulfite into the cephalosporin C preparation solution in the example 8 of the invention; meanwhile, the purity of the 7-ACA finished product is also improved.
The experimental results show that the preparation method of the invention improves the purity of the 7-ACA finished product by adding the antioxidant into the cephalosporin C preparation solution, obviously reduces the maximum unknown single impurity content in the obtained 7-ACA finished product, and improves the quality of the 7-ACA product.
In summary, the present invention provides a 7-ACA having a low content of maximum unknown impurities and a method for preparing the same, wherein the purity of the 7-ACA is above 99.10%, and the maximum content of the maximum unknown impurities is below 0.152%. According to the invention, the antioxidant is added into the cephalosporin C preparation solution, so that the generation of the maximum unknown single impurity in the enzymolysis reaction process can be effectively reduced, and the maximum unknown single impurity content in the final product 7-ACA can be effectively reduced; the method is simple to operate, is suitable for industrial mass production, overcomes the technical problem that the prior art is difficult to prepare the high-purity 7-ACA with low unknown single impurity content in the industrial mass production, and has wide application prospect.
Claims (10)
1. 7-aminocephalosporanic acid with a low content of the largest unknown single impurity, characterized in that: the purity of the 7-aminocephalosporanic acid is more than 99.10%, and the maximum content of unknown single impurities is less than 0.152%; the retention time of the largest unknown single impurity relative to 7-aminocephalosporanic acid under the following HPLC chromatographic conditions was 1.60 ± 0.10:
HPLC chromatographic conditions:
a chromatographic column: c18A chromatographic column is arranged on the top of the chromatographic column,
mobile phase: phase A: and the volume ratio of the phase B is 97:3, wherein the phase A is 0.02mol/L ammonium acetate solution, and the phase B is acetonitrile.
2. 7-aminocephalosporanic acid with a low content of the largest unknown simple impurity according to claim 1, characterized in that: in the HPLC chromatographic condition, the pH of the phase A is 6.2 +/-0.02; flow rate: 1.0 ml/min; column temperature: 35 ℃; detection wavelength: 254 nm.
3. A process for the preparation of 7-aminocephalosporanic acid with a low content of the largest unknown single impurity, characterized in that: the method comprises the following steps:
(1) adding an antioxidant into the cephalosporin C preparation solution, and uniformly mixing to obtain a pretreatment solution;
(2) carrying out enzymolysis reaction on the pretreatment solution obtained in the step (1) and enzyme to obtain 7-aminocephalosporanic acid enzymatic hydrolysate;
(3) and (3) performing ultrafiltration, crystallization and filtration on the enzymolysis liquid obtained in the step (2), and drying the solid to obtain the 7-aminocephalosporanic acid.
4. The production method according to claim 3, characterized in that: in the step (1), the antioxidant is one or a mixture of more than two of sodium bisulfite, sodium sulfite, sulfurous acid and sodium hydrosulfite;
and/or the antioxidant accounts for 0.20-0.30 wt.% of the mass of the cephalosporin C preparation liquid.
5. The method of claim 4, wherein: in the step (1), the antioxidant is sodium bisulfite;
and/or the mass of the antioxidant is 0.25 wt.% per mill of the mass of the cephalosporin C preparation liquid.
6. The production method according to claim 3, characterized in that: in the step (1), the cephalosporin C preparation solution is a cephalosporin C aqueous solution;
the titer of the cephalosporin C preparation liquid is 20000-30000 mu g/mL;
and/or the pH value of the pre-cephalosporin C preparation liquid is 7.5 +/-0.5.
7. The method of claim 6, wherein: in the step (1), the titer of the cephalosporin C preparation solution is 22500 mug/mL;
and/or the pH value of the pre-cephalosporin C preparation liquid is 7.5.
8. The production method according to claim 3, characterized in that: in the step (2), the enzyme is immobilized cephalosporin C acylase; the pH value of the enzymolysis reaction is 8.0-9.0, the temperature is 10-20 ℃, and the time is 50-120 minutes;
and/or in the step (3), the cut-off molecular weight of an ultrafiltration membrane adopted in ultrafiltration is 4000-6000 daltons; the crystal is isoelectric point crystal, and the pH value during the crystallization is 5.0-6.0.
9. The method of claim 8, wherein: in the step (2), the pH value of the enzymolysis reaction is 8.3, the temperature is 14 ℃, and the time is 80 minutes.
10. The method of claim 8, wherein: in the step (3), the molecular weight cut-off of the ultrafiltration membrane adopted by ultrafiltration is 5000 daltons; the pH at the time of the crystallization was 5.3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011628328.XA CN112625053B (en) | 2020-12-30 | 2020-12-30 | 7-ACA with low content of maximum unknown simple impurity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011628328.XA CN112625053B (en) | 2020-12-30 | 2020-12-30 | 7-ACA with low content of maximum unknown simple impurity and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112625053A true CN112625053A (en) | 2021-04-09 |
| CN112625053B CN112625053B (en) | 2022-08-09 |
Family
ID=75290538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011628328.XA Active CN112625053B (en) | 2020-12-30 | 2020-12-30 | 7-ACA with low content of maximum unknown simple impurity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112625053B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292577A (en) * | 2021-06-18 | 2021-08-24 | 伊犁川宁生物技术股份有限公司 | Method for preparing high-purity 7-ACA with short period and high yield |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1295575A (en) * | 1998-03-27 | 2001-05-16 | Dsm公司 | Novel process for fermentative production of cephalosporin |
| CN102154429A (en) * | 2010-12-28 | 2011-08-17 | 哈药集团制药总厂 | One-step enzymatic method for preparing 7-aminocephalosporanic acid |
| CN103429596A (en) * | 2011-03-03 | 2013-12-04 | 中化帝斯曼制药有限公司荷兰公司 | Degradation of penicillin compounds |
| CN104651439A (en) * | 2015-03-23 | 2015-05-27 | 石药集团中诺药业（石家庄）有限公司 | Enzymatic preparation process of 7-aminocephalosporanic acid |
| CN110283869A (en) * | 2019-07-05 | 2019-09-27 | 国药集团威奇达药业有限公司 | The preparation method of 7-amino-cephalosporanic acid |
| CN110423241A (en) * | 2019-07-05 | 2019-11-08 | 国药集团威奇达药业有限公司 | The preparation method of cephalosporin C Sodium and 7-amino-cephalosporanic acid |
-
2020
- 2020-12-30 CN CN202011628328.XA patent/CN112625053B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1295575A (en) * | 1998-03-27 | 2001-05-16 | Dsm公司 | Novel process for fermentative production of cephalosporin |
| CN102154429A (en) * | 2010-12-28 | 2011-08-17 | 哈药集团制药总厂 | One-step enzymatic method for preparing 7-aminocephalosporanic acid |
| CN103429596A (en) * | 2011-03-03 | 2013-12-04 | 中化帝斯曼制药有限公司荷兰公司 | Degradation of penicillin compounds |
| CN104651439A (en) * | 2015-03-23 | 2015-05-27 | 石药集团中诺药业（石家庄）有限公司 | Enzymatic preparation process of 7-aminocephalosporanic acid |
| CN110283869A (en) * | 2019-07-05 | 2019-09-27 | 国药集团威奇达药业有限公司 | The preparation method of 7-amino-cephalosporanic acid |
| CN110423241A (en) * | 2019-07-05 | 2019-11-08 | 国药集团威奇达药业有限公司 | The preparation method of cephalosporin C Sodium and 7-amino-cephalosporanic acid |
Non-Patent Citations (1)
| Title |
|---|
| 谭强等: "7-氨基头孢烷酸的制备工艺研究进展", 《现代化工》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292577A (en) * | 2021-06-18 | 2021-08-24 | 伊犁川宁生物技术股份有限公司 | Method for preparing high-purity 7-ACA with short period and high yield |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112625053B (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108602749B (en) | Method for producing ferulic acid from corn bran with high purity and high yield | |
| CN102040638B (en) | Method for preparing nonsolvent of high-purity natamycin | |
| CN110423241B (en) | Process for preparing cephalosporin C sodium salt and 7-aminocephalosporanic acid | |
| CN103555807B (en) | Method for preparing 7-ACA (aminocephalosporanic acid) and obtaining alpha-aminoadipic acid by one-step enzymatic reaction | |
| CN112195171A (en) | Method for preparing beta-alanine by using immobilized enzyme | |
| CN109265498B (en) | Method for preparing N-acetylneuraminic acid by integrated separation and purification of polysialic acid | |
| CN112979482B (en) | High-purity L-valine as well as preparation method and application thereof | |
| CN112625053B (en) | 7-ACA with low content of maximum unknown simple impurity and preparation method thereof | |
| CN110283869B (en) | Preparation method of 7-aminocephalosporanic acid | |
| CN104480181B (en) | The preparation method of 3- deacetyl-7-amino-cephemcarboxylic acids | |
| CN111171097A (en) | Separation and purification method for producing adenosine by fermentation | |
| CN102102115B (en) | Method for preparing calcium gluconate and isomaltooligosaccharide simultaneously with crystalline glucose mother liquor | |
| CN110407857B (en) | Preparation process of cefathiamidine | |
| CN105238841B (en) | Cephalosporin adsorbs the recycling of DCPC and method for transformation in waste liquid | |
| CN111362860A (en) | Method for extracting tryptophan from fermentation liquor | |
| CN105111285A (en) | Daptomycin extraction method | |
| CN108976270B (en) | Preparation method of high-purity doramectin | |
| CN113087895B (en) | Preparation method of high-molecular-weight cosmetic-grade polyglutamic acid | |
| CN110606844B (en) | Mupirocin purification method | |
| CN112939795B (en) | High-purity granular L-valine crystal, and preparation method and application thereof | |
| CN110452275B (en) | Preparation method of high-purity kasugamycin | |
| CN117050021B (en) | Method for separating and extracting tetrahydropyrimidine from fermentation liquor | |
| CN113045610A (en) | Method for extracting glucosamine from N-acetylglucosamine fermentation liquor | |
| CN112028784A (en) | Preparation method of free L-lysine solid | |
| CN113637024B (en) | Method for purifying deacetyloxy cephalosporin C aqueous solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |